I'm confused... Are you saying the ongoing MAPS FDA Phase 3 trials [0] are more about safety than efficacy? The whole point of Phase 3 trials is to prove efficacy.
Additionally, earlier studies [1] measured the participant's CAPS (Clinician Administered PTSD Scale) pre and post treatment which showed pretty significant results.